The Valley Desk

ArticleDermatology and therapyPublished

Safety of Icotrokinra Through 1 Year for the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriasis Affecting High-Impact Sites: Pooled Results Across the ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 and 2 Phase 3 Trials

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Article
Venue
Dermatology and therapy
Published
Subject terms
Safety; Psoriasis; Oral; Deucravacitinib; Icotrokinra
PubMed ID
42663861
PubMed Central ID
PMC13650227
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal